Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
LAURA trial
May 25, 2024, 14:28 |
Blog
Studies conducted by Dana-Farber at this year’s AACR Annual Meeting
Dana-Farber Cancer Institute shared on LinkedIn: "Numerous studies conducted by Dana-Farber researchers show promising results for…
May 21, 2024, 08:21 |
Societies
20 Posts Not To Miss From SIOP Europe 2024!
The 5th SIOP Europe Annual Meeting took place in Milan, Italy on 13-17 May 2024.…
May 13, 2024, 08:08 |
Blog
Monica Bertagnolli: Fascinating research I recently read about CAR-T therapy
Monica Bertagnolli shared a post on LinkedIn: ''Fascinating research I recently read about in the New…
May 2, 2024, 15:25 |
Blog
Tanja Obradovic: Interesting updates will be coming on ASCO 2024
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared on LinkedIn: "ASCO 2024 is almost…
May 2, 2024, 12:01 |
Blog
Ramy Sedhom: In lockstep with the ASCO Presidential Theme - Palliative Care is on the stage as a plenary at this year's Annual Meeting
Ramy Sedhom, Clinical Director of Palliative Care at Penn Medicine Princeton Health, shared a post…
Apr 25, 2024, 12:59 |
Societies
Chitkala Kalidas: It was a pleasure participating in the industry panel discussion at Cancer Drug Development Forum
Chitkala Kalidas, Vice President, Global Head of Oncology at Bayer shared a post on LinkedIn:…
Apr 14, 2024, 07:51 |
Insight
New Paper Alert! Defining Dermatologic Immune-Related Adverse Events: A Consensus-Driven Approach
Defining Dermatologic Immune-Related Adverse Events: A Consensus-Driven Approach Published in Journal for ImmunoTherapy of Cancer,…
Apr 4, 2024, 13:34 |
Drugs
Erman Akkus: NSCLC and anti-EGFR treatments from the ASCO Educational Book
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "NSCLC and anti-EGFR treatments…
Mar 8, 2024, 20:11 |
Blog
Ramy Sedhom: The new ASCO guideline represents amazing advances for pts with NSCLC and driver alterations
Ramy Sedhom, Clinical Director of Palliative Care at Penn Medicine Princeton Health, shared a post on…
Feb 17, 2024, 15:57 |
Insight
Rami Manochakian: The FDA approves 1st line Osimertinib WITH chemotherapy for advanced EGFRm NSCLC.
Rami Manochakian, Thoracic Oncologist and Hematology-Oncology Fellowship Director at Mayo Clinic, shared on X/Twitter: "Hot off…
8
9
10
11
12
All:
120
Posts:
101 - 110
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 6
ASTRO24: 15 Posts Not To Miss From Day 4
Top 100 Xfluencers in Prostate Cancer: Key Opinion Leaders to follow on X (Twitter) in 2024
Paper Alert! Cutaneous Metastases in Thyroid Cancer: A Comprehensive Review of 136 Cases
ASTRO 24: 15 Posts Not to Miss From Day 3
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube